Skip to content
value.today

Caldera Pharmaceuticals Inc

Total raised
$25 M
7 rounds on record
Latest round
$7 M
Aug 2018
First round on record
May 2011
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Caldera Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2018$7 MNo. 7$2 to $10 million

Caldera Pharmaceuticals Inc: Raise no. 7, Aug 2018

Investors in this round

1 investor had bought by the notice of Sep 12, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$307,500
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Krafte · Executive Officer
  • Mark Korb · Executive Officer
  • Richard Cunningham · Executive Officer
  • Clive Kabatznik · Director
  • Edward Roffman · Director
  • Michael Taglich · Director
  • Timothy Tyson · Director
  • Vincent Palmieri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used to pay overhead and other corporate expenses which could include salaries.”

Signed by Richard Cunningham, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 12, 2018. Read the notice at the SEC.

debt, optionsSEC
Apr 2018$2 MNo. 6$2 to $10 million

Caldera Pharmaceuticals Inc: Raise no. 6, Apr 2018

Investors in this round

1 investor had bought by the notice of Apr 12, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
$100,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Korb · Executive Officer
  • Richard Cunningham · Executive Officer
  • Clive Kabatznik · Director
  • Douglas Krafte · Director
  • Edward Roffman · Director
  • Michael Taglich · Director
  • Timothy Tyson · Director
  • Vincent Palmieri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “*Proceeds may be used to pay overhead and other corporate expenses which could includesalaries”

Signed by Richard Cunningham, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 12, 2018. Read the notice at the SEC.

equity, optionsSEC
Apr 2017$2 MNo. 5Under $2 million

Caldera Pharmaceuticals Inc: Raise no. 5, Apr 2017

Investors in this round

3 investors had bought by the notice of Apr 28, 2017: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$500,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$60,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Krafte · Executive Officer
  • Mark Korb · Executive Officer
  • Richard Cunningham · Executive Officer
  • Benjamin Warner · Director
  • Clive Kabatznik · Director
  • Edward Roffman · Director
  • Michael Taglich · Director
  • Timothy Tyson · Director
  • Vincent Palmieri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • "TAGLICH BROTHERS, INC. (""TAGLICH"")" (CRD 29102) · New York, New YorkSold in CT, NY

Remarks in the notice

  • On fees: “*Designees of Taglich also received a warrant to acquire 25,000 shares of common stock as compensation”
  • On the amounts: “*The amount being raised was a minimum of $1,000,000”
  • On the use of proceeds: “*Proceeds may be used to pay overhead and other corporate expenses which could include salaries”

Signed by Richard Cunningham, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 28, 2017. Read the notice at the SEC.

debt, optionsSEC
Jun 2016$1 MNo. 4Under $2 million

Caldera Pharmaceuticals Inc: Raise no. 4, Jun 2016

Investors in this round

12 investors had bought by the notice of Jul 8, 2016: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$10,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$68,700
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Krafte · Executive Officer
  • Mark Korb · Executive Officer
  • Richard Cunningham · Executive Officer
  • Benjamin Warner · Director
  • Clive Kabatznik · Director
  • Edward Roffman · Director
  • Michael Taglich · Director
  • Timothy Tyson · Director
  • Vincent Palmieri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Taglich Brothers, Inc. (CRD 29102) · New York, New YorkSold in CA, FL, KS, MI, NY

Remarks in the notice

  • On the amounts: “*The amount being raised was a minimum of $1,000,000”

Signed by Richard Cunningham, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 8, 2016. Read the notice at the SEC.

debt, optionsSEC
Dec 2014$9 MNo. 3$2 to $10 million

Caldera Pharmaceuticals Inc: Raise no. 3, Dec 2014

Investors in this round

162 investors had bought by the notice of Jan 15, 2015: 162 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, other: Warrant is exercisable for Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$708,400
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin Warner · Executive Officer, Director
  • Mark Korb · Executive Officer
  • Richard Cunningham · Executive Officer
  • Clive Kabatznik · Director
  • Edward Roffman · Director
  • Michael Taglich · Director
  • Timothy Tyson · Director
  • Vincent Palmieri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Taglich Brothers, Inc. (CRD 29102) · New York, New YorkSold in AZ, CA, CO, CT, FL, GA, IA, IL, IN, KS, MA, MD, MI, MN, MO, NC, NH, NJ, NV, NY, OH, OK, PA, SC, SD, TN, TX, VA, WA, WI

Signed by Richard Cunningham, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 15, 2015. Read the notice at the SEC.

equity, optionsSEC
Apr 2013$3 MNo. 2$2 to $10 million

Caldera Pharmaceuticals Inc: Raise no. 2, Apr 2013

Investors in this round

61 investors had bought by the notice of May 10, 2013: 61 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$282,150
Finders' fees
none
Paid to its own people
$250,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin Warner · Executive Officer, Director
  • Edward Roffman · Director
  • Jeremiel Zimmerman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • VINCENT PALMIERI · broker-dealer Taglich Brothers, Inc. (CRD 29102) · Huntington, New YorkSold in AR, CA, CO, CT, IA, IN, KS, KY, ME, MI, MN, MO, NC, NE, NH, NM, NY, OH, OK, PA, SC, TN, WI

Remarks in the notice

  • On fees: “Includes value of warrants to purchase common shares issued without consideration.”
  • On the amounts: “Includes $375,000 of convertible debt that converted into 150,000 units in the offering”

Signed by Benjamin Warner, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed May 10, 2013. Read the notice at the SEC.

equity, optionsSEC
May 2011$1 MNo. 1Under $2 million

Caldera Pharmaceuticals Inc: Raise no. 1, May 2011

Investors in this round

0 investors had bought by the notice of May 19, 2011: 0 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Caldera Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin Warner · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Benjamin Warner, Ceo. Source: SEC Form D, newest notice filed May 19, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Caldera Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Sep 2018).

    SEC Form D · Sep 2018

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2018

That is all the official record says: Caldera Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Caldera Pharmaceuticals Inc
InvestorKindAmountRoundRoleSource
Benjamin WarnerPersonnot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
Michael N. TaglichPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2013)SEC Form 3
Vincent PalmieriPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 162 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Caldera Pharmaceuticals Inc
NameRoleNamed in
Douglas KrafteExecutive officerSep 2018
Mark KorbExecutive officerSep 2018
Richard CunninghamExecutive officerSep 2018
Benjamin WarnerExecutive officerJan 2015
Clive KabatznikDirectorSep 2018
Edward RoffmanDirectorSep 2018
Michael TaglichDirectorSep 2018
Timothy TysonDirectorSep 2018
Vincent PalmieriDirectorSep 2018
Douglas KrafteDirectorApr 2018
Benjamin WarnerDirectorApr 2017
Jeremiel ZimmermanDirectorMay 2013